FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4231279863> ?p ?o ?g. }

• W4231279863 endingPage "3014" @default.
• W4231279863 startingPage "3014" @default.
• W4231279863 abstract "Abstract Resistance of tumor cells to the induction of apoptosis is an important reason for the failure of anticancer treatments in patients with gliomas. Several factors working in concert have been implicated as sources of this treatment resistance; therefore, innovative therapeutic approaches that conspire to attack key tumor vulnerabilities are needed. HDAC and proteasome inhibitors are two classes of agents that have shown some benefit in the clinic, but patients often rapidly manifest intrinsic or acquired resistance mechanisms that limits their individual efficacy. We demonstrate that the combination of the HDAC inhibitor panobinostat and the proteasome inhibitor bortezomib synergistically induces apoptosis of human glioma cell lines. However, acquired resistance is observed even with this initially effective combination. To examine the mechanism of this resistance, we performed RNA sequencing and pharmacological screening of resistant compared to sensitive cells. Based on these studies, we present evidence that quinolinic acid phosphoribosyltransferase (QPRT), an enzyme catalyzes a rate determining step in de novo NAD+ biosynthesis, provides a critical adaptive survival mechanism that allows cancer cells to evade an initially effective therapeutic combination. We identified 1004 genes that had a significant change between panobinostat and bortezomib- resistant cells versus inhibitor naïve control cells. Furthermore, pathway analysis revealed that the experimental regimen significantly altered metabolic pathways. By silencing QPRT (using siRNA) we demonstrated that we can overcome resistance, thus suggesting QPRT as a crucial crossroad for cancer cell survival and as a new anticancer target. We also showed that treatment of panobinostat and bortezomib resistant cells with FK866, niraparib, selisistat, epacadostat, gemcitabine, 5-fluoruracil, and methotrexate significantly increased cell death highlighting the importance of NAD+ and folate pathway inhibitors in resensitizing the resistant cells. Together, targeting QPRT or NAD+ consuming enzymes hold promise for eliminating recurrent disease in glioma. Citation Format: Esther P. Jane, Daniel R. Premkumar, Sameer Agnihotri, Max Myers, Ansuman Chattopadhyay, D. Lansing Taylor, Mark Schurdak, Andrew Stern, Ian F. Pollack. Gene signatures identify quinolate phosphoribosyltransferase as a key mediator of acquired resistance to Panobinostat and Bortezomib in glioma, and NAD+ biosynthesis as a targetable pathway to reverse treatment resistance [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 3014." @default.
• W4231279863 created "2022-05-12" @default.
• W4231279863 creator A5015468249 @default.
• W4231279863 creator A5042570169 @default.
• W4231279863 creator A5046535003 @default.
• W4231279863 creator A5051585662 @default.
• W4231279863 creator A5056492340 @default.
• W4231279863 creator A5060216832 @default.
• W4231279863 creator A5071660155 @default.
• W4231279863 creator A5080784534 @default.
• W4231279863 creator A5081552804 @default.
• W4231279863 date "2019-07-01" @default.
• W4231279863 modified "2023-09-27" @default.
• W4231279863 title "Abstract 3014: Gene signatures identify quinolate phosphoribosyltransferase as a key mediator of acquired resistance to Panobinostat and Bortezomib in glioma, and NAD+ biosynthesis as a targetable pathway to reverse treatment resistance" @default.
• W4231279863 doi "https://doi.org/10.1158/1538-7445.am2019-3014" @default.
• W4231279863 hasPublicationYear "2019" @default.
• W4231279863 type Work @default.
• W4231279863 citedByCount "0" @default.
• W4231279863 crossrefType "journal-article" @default.
• W4231279863 hasAuthorship W4231279863A5015468249 @default.
• W4231279863 hasAuthorship W4231279863A5042570169 @default.
• W4231279863 hasAuthorship W4231279863A5046535003 @default.
• W4231279863 hasAuthorship W4231279863A5051585662 @default.
• W4231279863 hasAuthorship W4231279863A5056492340 @default.
• W4231279863 hasAuthorship W4231279863A5060216832 @default.
• W4231279863 hasAuthorship W4231279863A5071660155 @default.
• W4231279863 hasAuthorship W4231279863A5080784534 @default.
• W4231279863 hasAuthorship W4231279863A5081552804 @default.
• W4231279863 hasConcept C104317684 @default.
• W4231279863 hasConcept C181199279 @default.
• W4231279863 hasConcept C203014093 @default.
• W4231279863 hasConcept C2776364478 @default.
• W4231279863 hasConcept C2777478702 @default.
• W4231279863 hasConcept C2778305200 @default.
• W4231279863 hasConcept C2778367456 @default.
• W4231279863 hasConcept C2780108899 @default.
• W4231279863 hasConcept C2780225316 @default.
• W4231279863 hasConcept C2780391879 @default.
• W4231279863 hasConcept C502942594 @default.
• W4231279863 hasConcept C55493867 @default.
• W4231279863 hasConcept C64927066 @default.
• W4231279863 hasConcept C75520062 @default.
• W4231279863 hasConcept C86803240 @default.
• W4231279863 hasConcept C98274493 @default.
• W4231279863 hasConceptScore W4231279863C104317684 @default.
• W4231279863 hasConceptScore W4231279863C181199279 @default.
• W4231279863 hasConceptScore W4231279863C203014093 @default.
• W4231279863 hasConceptScore W4231279863C2776364478 @default.
• W4231279863 hasConceptScore W4231279863C2777478702 @default.
• W4231279863 hasConceptScore W4231279863C2778305200 @default.
• W4231279863 hasConceptScore W4231279863C2778367456 @default.
• W4231279863 hasConceptScore W4231279863C2780108899 @default.
• W4231279863 hasConceptScore W4231279863C2780225316 @default.
• W4231279863 hasConceptScore W4231279863C2780391879 @default.
• W4231279863 hasConceptScore W4231279863C502942594 @default.
• W4231279863 hasConceptScore W4231279863C55493867 @default.
• W4231279863 hasConceptScore W4231279863C64927066 @default.
• W4231279863 hasConceptScore W4231279863C75520062 @default.
• W4231279863 hasConceptScore W4231279863C86803240 @default.
• W4231279863 hasConceptScore W4231279863C98274493 @default.
• W4231279863 hasIssue "13_Supplement" @default.
• W4231279863 hasLocation W42312798631 @default.
• W4231279863 hasOpenAccess W4231279863 @default.
• W4231279863 hasPrimaryLocation W42312798631 @default.
• W4231279863 hasRelatedWork W155247308 @default.
• W4231279863 hasRelatedWork W1850271161 @default.
• W4231279863 hasRelatedWork W2063424779 @default.
• W4231279863 hasRelatedWork W2149340130 @default.
• W4231279863 hasRelatedWork W2269989009 @default.
• W4231279863 hasRelatedWork W2339624602 @default.
• W4231279863 hasRelatedWork W2521212135 @default.
• W4231279863 hasRelatedWork W2612089043 @default.
• W4231279863 hasRelatedWork W2738602720 @default.
• W4231279863 hasRelatedWork W3184357652 @default.
• W4231279863 hasVolume "79" @default.
• W4231279863 isParatext "false" @default.
• W4231279863 isRetracted "false" @default.
• W4231279863 workType "article" @default.